CMA Recommendations on Vaccine Equity and Intellectual Property

https://policybase.cma.ca/link/policy14476

POLICY TYPE
Parliamentary submission

DATE
2022-05-13

TOPICS
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA Recommendations on Vaccine Equity and Intellectual Property

House of Commons Standing Committee on Foreign Affairs and International Development

May 12, 2022
Policy Brief: CSAM-SMCA in Support of the Decriminalization of Drug Use and Possession for Personal Use
https://policybase.cma.ca/link/policy14443

POLICY TYPE  Policy endorsement
DATE       2021-06-24
TOPICS     Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

INTRODUCTION

Contrary to popular opinion, there is substantial support for limiting the use of police resources in regulating non-criminalized drug use. However, drug use regulation is a complex issue that involves multiple factors. This paper outlines the rationale behind the decriminalization of drug use and discusses the potential benefits of this approach. It highlights the importance of addressing the social determinants of health and the need for comprehensive harm reduction strategies.

SYNOPSIS OF POLICY

Decriminalization of drug use is a public health strategy aimed at reducing the harms associated with drug use. It involves shifting the focus from criminalization to harm reduction, which includes providing access to treatment, support, and assistance. The goal is to minimize the negative consequences of drug use while promoting public health and well-being. This approach recognizes the complexity of drug use and seeks to address the underlying social and environmental factors that contribute to drug use.

DOCUMENTS

- Taking action on drug shortages during Covid-19 - open letter
- CMA Policybase - Canadian Medical Association
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE
Parliamentary submission

DATE
2020-08-13

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Dear [Recipient],

We are writing to you today to raise our collective concern and request action on drug shortages in Canada, especially in the context of the COVID-19 pandemic.

As the pandemic continues to evolve, the demand for certain medications has increased, and this has put a strain on the supply chain. The Canadian Medical Association (CMA) and the Canadian Pharmacists Association (CPA) have been working closely to address these challenges.

The pandemic has highlighted the importance of having robust systems in place to ensure the availability of essential medications. It has also underscored the need for enhanced collaboration among stakeholders, including governments, healthcare providers, and pharmaceutical companies.

We recommend that the federal government take the lead in coordinating efforts across provinces and territories to ensure a coordinated response to drug shortages. This could involve creating a national drug shortage management plan, establishing a central database to track shortages, and increasing funding for research and development of new medications.

We also urge the government to consider the use of emergency measures, such as temporary importation of drugs, to address short-term shortages. These measures should be aligned with international law and governance frameworks.

In conclusion, while the pandemic has presented significant challenges, it also presents an opportunity to strengthen our healthcare system and ensure that Canadians have access to the medications they need.

Sincerely,

[Your Name]
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE  Response to consultation
DATE       2019-05-24
TOPICS     Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

Policy document

2019-03-03

Pharmaceuticals, prescribing, cannabis, drugs

The Canadian Medical Association (CMA) has recognized the growing importance of how individuals suffering from terminal illness or chronic disease for which conventional therapies have not been effective are seeking to gain access to cannabis.

However, there is a need to ensure that the use of cannabis is consistent with the law and the public interest. The CMA believes that the use of cannabis for medicinal purposes should be regulated in a manner that is consistent with the public interest.

The CMA supports the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis. The CMA recommends increasing support for scientific research. A sound evidence base for the medical use of cannabis is necessary for the development of appropriate regulations.

2. Apply the same regulatory oversight and safety requirements to cannabis as to other pharmaceuticals. The CMA recommends that cannabis be regulated in a manner consistent with the regulations for other pharmaceutical products.

3. Increase support for palliative care for patients and their families. The CMA recommends increased support for palliative care services. A sound evidence base for the medical use of cannabis is necessary for the development of appropriate regulations.

The CMA continues to support the need for a sound evidence base for the medical use of cannabis. It recommends that appropriate research be supported to advance the field of medical cannabis.
Medication use and seniors (Update 2017)

https://policybase.cma.ca/link/policy10151

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2011-05-28

REPLACES
Medication use and seniors

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document

LAST REVIEWED  2019-03-03

DATE  2012-12-08

TOPICS  Health information and e-health

Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE         Response to consultation
DATE               2019-02-20
TOPICS             Pharmaceuticals, prescribing, cannabis, drugs
                   Population health, health equity, public health

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE: Response to consultation
DATE: 2018-12-04
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE          Response to consultation
DATE                2018-10-02
TOPICS              Health care and patient safety
                                      Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-09-06</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety, Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

Documents

CMA response:

HEALTH CANADA CONSULTATION ON TOBACCO PRODUCTS REGULATIONS (PLAIN AND STANDARDIZED APPEARANCE)

September 30, 2018
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE
Policy endorsement

DATE
2018-08-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE
Response to consultation

DATE
2018-08-14

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE  Response to consultation
DATE  2018-07-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE: Response to consultation

DATE: 2018-04-23

TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear Dr. "Kempk":

The Canadian Medical Association appreciates the opportunity to participate in the consultation on proposed front-of-package labelling as part of Bill C-45: The Cannabis Act. As a member of the public, I consider it my responsibility to contribute to the debate in a constructive and informed manner. The following points are intended to provide some feedback on the proposed rules for cannabis labelling, and include comments on four key areas of concern.

First, the definition of health and patient safety. The Federal, Provincial and Territorial Advisory Committee on the Safe and Effective Use of Cannabis (ACSEU) has acknowledged the need for clear and concise labelling information. The Canadian Food Inspection Agency (CFIA) has also noted that clear labelling is critical to ensuring that consumers have access to accurate information about the products they purchase. However, the proposed rules for cannabis labelling fall short of these standards.

Specifically, the proposed rules for cannabis labelling fail to address the issue of health and patient safety in a meaningful way. The rules are vague and do not provide clear guidance on how to ensure that consumers have access to accurate information about the products they purchase. As such, the proposed rules for cannabis labelling are insufficient to meet the needs of consumers.

Second, the definition of health and patient safety. The proposed rules for cannabis labelling fall short of these standards.

Third, the definition of health and patient safety. The proposed rules for cannabis labelling fall short of these standards.

Fourth, the definition of health and patient safety. The proposed rules for cannabis labelling fall short of these standards.

It is important to note that the proposed rules for cannabis labelling fail to address the issue of health and patient safety in a meaningful way. The rules are vague and do not provide clear guidance on how to ensure that consumers have access to accurate information about the products they purchase. As such, the proposed rules for cannabis labelling are insufficient to meet the needs of consumers.

In conclusion, I urge the CFIA to consider the feedback provided by the Canadian Medical Association and to work with the ACSEU to develop clear and concise labelling rules that meet the needs of consumers. The proposed rules for cannabis labelling fail to address the issue of health and patient safety in a meaningful way. The rules are vague and do not provide clear guidance on how to ensure that consumers have access to accurate information about the products they purchase. As such, the proposed rules for cannabis labelling are insufficient to meet the needs of consumers.

Yours sincerely,

[Your Name]

[Your Contact Information]
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE          Parliamentary submission
DATE                2018-04-18
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Bill C-45: The Cannabis Act

Submission to the Senate Standing Committee, Social Affairs, Science & Technology

April 18th, 2018
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

POLICY TYPE	Parliamentary submission
DATE	2018-02-15
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE  Response to consultation
DATE  2018-01-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Submission: Excise Duty Framework for Cannabis Products

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017